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Cyclin-dependent kinase inhibitors (CDKi) are considered as a suitable 
treatment especially in patients with wrong prognosis or advanced stage of cancer.  
It has only recently been discovered that CDKi are able to influence the activity of some 
enzymes from aldo-keto reductase (AKR) and short-chain dehydrogenase/reductase 
(SDR) superfamilies.  
AKR and SDR enzymes belong to a group of carbonyl reducing enzymes that 
are involved in the metabolism of endobiotics and xenobiotics. An important group 
of drugs that are metabolized by these enzymes to less efficient compounds are 
anthracyclines.  
The aim of this diploma thesis was to find out whether purvalanol A, roscovitin, 
dinaciclib, AZD5438 and R547 can affect the expression of the most important 
anthracycline reductases (AKR1A1, AKR1B10, AKR1C3, AKR7A2 and CBR1) 
in human HepG2 and HL-60 cell lines.  
Expression of anthracycline reductases in cells exposed to CDKi was evaluated 
at mRNA level by RT-qPCR and at protein level by Western blotting. The most 
significant changes in mRNA expression were observed for roscovitin and purvalanol 
A. Roscovitin caused a statistically significant reduction in mRNA expression of the 
AKR1A1, AKR1B10, AKR7A2 and CBR1 enzymes. Decreased expression 
of AKR1A1 and AKR7A2 enzymes at mRNA level was detected also in the case 
of purvalanol A. Expression at protein level was evaluated only for AKR1C3. However, 
no statistically significant changes were observed. 
